Clinical trials in Regensburg – page 15

319 clinical trials in Regensburg, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Regensburg at a glance

319

clinical trials

Research sites2

Quick filters

319 trials in Regensburg

Open in trial search

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Pancreatic carcinoma metastatic

Not yet recruiting

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:University Of Cologne

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Neuroblastoma

Not yet recruiting

Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

Registered drugNo placebo

Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:University Of Cologne

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Diffuse large B-cell lymphoma refractory

Not recruiting

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Gastric cancer+6

Not recruiting

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cldn6 Car-T
Sponsor:BioNTech Cell & Gene Therapies GmbH

Contact Research Centre

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tuvusertib
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Pulmonary arterial hypertension

Not recruiting

A Study of PF-07868489 Safety and Effectiveness in Adults with Pulmonary Arterial Hypertension Who Participated in a Previous PF-07868489 Trial

InvestigationalNo placebo

A Study of PF-07868489 Safety and Effectiveness in Adults with Pulmonary Arterial Hypertension Who Participated in a Previous PF-07868489 Trial

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:PF-07868489
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Regensburg

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of targeted therapies for HR-positive and HER2-negative variants. Research extends to lymphoma and leukemia treatments, with particular emphasis on combination therapies.

Breast Cancer Therapeutics
Blood Cancer Treatments
Glioma Research

Multiple studies are evaluating novel drug combinations and their impact on patient survival rates.

02 Dermatology Studies

Research focusing on preventive treatments for atopic dermatitis in high-risk pediatric populations, evaluating the effectiveness of early intervention strategies.

Pediatric Skin Conditions
Preventive Dermatology
Chronic Skin Disorders

Studies aim to establish new preventive protocols for childhood dermatological conditions.

03 Respiratory Medicine

Investigations into treatments for pulmonary arterial hypertension and lung fibrosis, with emphasis on novel therapeutic approaches and drug safety profiles.

Pulmonary Hypertension
Autoimmune Lung Diseases
Viral Lung Infections

Current trials are exploring innovative treatments for various respiratory conditions.

Back to Germany All countries